Targeting the Achilles' Heel of Multidrug-Resistant Staphylococcus aureus by the Endocannabinoid Anandamide

Int J Mol Sci. 2022 Jul 14;23(14):7798. doi: 10.3390/ijms23147798.

Abstract

Antibiotic-resistant Staphylococcus aureus is a major health issue that requires new therapeutic approaches. Accumulating data suggest that it is possible to sensitize these bacteria to antibiotics by combining them with inhibitors targeting efflux pumps, the low-affinity penicillin-binding protein PBP2a, cell wall teichoic acid, or the cell division protein FtsZ. We have previously shown that the endocannabinoid Anandamide (N-arachidonoylethanolamine; AEA) could sensitize drug-resistant S. aureus to a variety of antibiotics, among others, through growth arrest and inhibition of drug efflux. Here, we looked at biochemical alterations caused by AEA. We observed that AEA increased the intracellular drug concentration of a fluorescent penicillin and augmented its binding to membrane proteins with concomitant altered membrane distribution of these proteins. AEA also prevented the secretion of exopolysaccharides (EPS) and reduced the cell wall teichoic acid content, both processes known to require transporter proteins. Notably, AEA was found to inhibit membrane ATPase activity that is necessary for transmembrane transport. AEA did not affect the membrane GTPase activity, and the GTPase cell division protein FtsZ formed the Z-ring of the divisome normally in the presence of AEA. Rather, AEA caused a reduction in murein hydrolase activities involved in daughter cell separation. Altogether, this study shows that AEA affects several biochemical processes that culminate in the sensitization of the drug-resistant bacteria to antibiotics.

Keywords: Staphylococcus aureus; anandamide; antibiotic resistance; autolysins; drug sensitization; endocannabinoids; transmembrane transport; wall teichoic acid.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Arachidonic Acids
  • Biochemical Phenomena*
  • Endocannabinoids / metabolism
  • Endocannabinoids / pharmacology
  • GTP Phosphohydrolases / metabolism
  • Humans
  • Methicillin-Resistant Staphylococcus aureus* / metabolism
  • Polyunsaturated Alkamides / metabolism
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus / metabolism

Substances

  • Anti-Bacterial Agents
  • Arachidonic Acids
  • Endocannabinoids
  • Polyunsaturated Alkamides
  • GTP Phosphohydrolases
  • anandamide

Grants and funding

This research received no external funding.